Description: Silo Pharma, Inc. operates as a developmental stage biopharmaceutical company. The company focuses on merging traditional therapeutics with psychedelic research for patients with depression, post-traumatic stress disorder, Alzheimer's, Parkinson's, and other rare neurological disorders. It has a scientific research agreement with the University of Maryland, The Regents of the University of California, and Columbia University. The company was formerly known as Uppercut Brands, Inc. and changed its name to Silo Pharma, Inc. in September 2020. Silo Pharma, Inc. was incorporated in 2010 and is headquartered in Englewood Cliffs, New Jersey.
Home Page: silopharma.com
SILO Technical Analysis
560 Sylvan Avenue
Englewood Cliffs,
NJ
07632
United States
Phone:
718 400 9031
Officers
| Name | Title |
|---|---|
| Mr. Eric Weisblum | Chairman, Pres & CEO |
| Mr. Daniel E. Ryweck | Chief Financial Officer |
| Dr. James S. Kuo M.B.A., M.D. | VP of R&D |
Exchange: NASDAQ
Country: US
Currency: US Dollar ($)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0.8563 |
| Price-to-Book MRQ: | 0.8553 |
| Price-to-Sales TTM: | 140.6109 |
| IPO Date: | 2014-05-13 |
| Fiscal Year End: | December |
| Full Time Employees: | 2 |